Eli Lilly's obesity drug beats rival in head-to-head trial, where Cramer thinks stock will be next
The new trial data has cemented Club's lead position behind Eli Lilly in the highly competitive anti-obesity drug race. Eli…
taking stock
Jim Cramer on Eli Lilly (LLY) after Trump picks RFK Jr. to lead HHS
Enthusiasm for Eli Lilly, the club's holding company, needs to be tempered, at least for now, as Wall Street grapples…
Abbott 'very cheap' after surprising legal victory validates our conviction
Shares of Abbott Laboratories rose on Friday after the Club holding company scored a surprise victory in a trial into…
GE Healthcare has been an under-the-radar winner and a new catalyst has just arrived
GE Healthcare's quiet outperformance is becoming harder to ignore, and its new drug used in radiology to improve the diagnosis…
Catalyst Calendar: Here's a Look at the Major Events That Could Drive These 7 Stocks Higher
AI technology stocks have been all the rage on Wall Street. But here are some events that could boost other…
Cramer says it's better to come to Oracle, also look at BIRK, JNJ, PARA, CASY
Jim Cramer's daily rapid-fire breaks down stocks in the news outside of the CNBC Investing Club portfolio. Oracle: The tech…
The promise of Eli Lilly's weight-loss drug for sleep apnea adds reasons to own it
Eli Lilly's weight-loss drug Zepbound showed promise as a treatment for sleep apnea, giving investors more confidence to continue owning…
Jim Cramer defends Elon Musk's use of ketamine for depression
CNBC's Jim Cramer said Tuesday that Elon Musk's revelation that he takes prescription ketamine for depression was brave and “saved…
Buy This Vertiv Data Center Company Despite Its Weak Guidance
Vertiv Holdings: The data center equipment maker, whose stock has roughly quadrupled over the past year, issued guidance that fell…
What Eli Lilly Investors Can Learn from the Slow Launch of a Rival Drug
Club holding company Eli Lilly hopes to win approval for its Alzheimer's treatment in the coming weeks, but investors looking…